Amanote Research
Register
Sign In
1p21 Deletions Are Strongly Associated With 1q21 Gains and Are an Independent Adverse Prognostic Factor for the Outcome of High-Dose Chemotherapy in Patients With Multiple Myeloma
Bone Marrow Transplantation
- United Kingdom
doi 10.1038/bmt.2009.158
Full Text
Open PDF
Abstract
Available in
full text
Categories
Transplantation
Hematology
Date
January 1, 2010
Authors
H Chang
X Qi
A Jiang
W Xu
Y Trieu
D Reece
Publisher
Springer Science and Business Media LLC
Related search
Chemotherapy Adherence Is a Favorable Prognostic Factor for Elderly Patients With Multiple Myeloma Who Are Treated With a Frontline Bortezomib-Containing Regimen
Yeungnam University Journal of Medicine
Phase II Study of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
British Journal of Haematology
Hematology
Single-Agent Thalidomide for Treatment of First Relapse Following High-Dose Chemotherapy in Patients With Multiple Myeloma
Leukemia
Cancer Research
Oncology
Anesthesiology
Pain Medicine
Hematology
Lymphatic Invasion Is an Independent Adverse Prognostic Factor in Patients With Colorectal Liver Metastasis
Annals of Surgical Oncology
Oncology
Surgery
1q21 Gain Combined With High‐Risk Factors Is a Heterogeneous Prognostic Factor in Newly Diagnosed Multiple Myeloma: A Multicenter Study in China
Oncologist
Cancer Research
Medicine
Oncology
Pre‑treatment Hemoglobin Levels Are an Independent Prognostic Factor in Patients With Non‑small Cell Lung Cancer
Molecular and Clinical Oncology
Cancer Research
Oncology
Fractal Characteristics of May-Grünwald-Giemsa Stained Chromatin Are Independent Prognostic Factors for Survival in Multiple Myeloma
PLoS ONE
Multidisciplinary
Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation
Clinical Lymphoma, Myeloma and Leukemia
Cancer Research
Oncology
Hematology
EMMPRIN Is an Independent Negative Prognostic Factor for Patients With Astrocytic Glioma
PLoS ONE
Multidisciplinary
